Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
Pleiotropy in Drosophila organogenesis: Mechanistic insights from Combgap and the retinal determination gene network.
Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
View in:
PubMed
subject areas
Adult
Aged
Carcinoma, Non-Small-Cell Lung
Central Nervous System Neoplasms
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Mutation
Neoplasm Proteins
Oncogene Proteins, Fusion
Organophosphorus Compounds
Pyrazoles
Pyridines
Pyrimidines
Receptor Protein-Tyrosine Kinases
authors with profiles
Ravi Salgia